


Shaping extracellular vesicle fate through functional protein corona formation for liver fibrosis treatment

Revadee Liam-Or, Calvin Chun Long Cheung, Debajyoti Chowdhury, Khuloud Al-Jamal

The research work described in this poster was conducted in the JC STEM Lab of Nanomedicine for Advanced Therapy funded by The Hong Kong Jockey Club Charities Trust.



INTRODUCTION

Liver fibrosis problem

- Progressive inflammatory disease
- No approved anti-fibrotic therapy.
- MSC-EVs are promising but rapidly cleared.

Previous finding

Albumin corona improved liver targeting and retention (1).

Current hypothesis

Optimized corona engineering can enhance EV functionality and enable therapeutic surface loading.

Methods

STEP 1: Generation of corona-functionalized EV libraries

MSC-EVs were generated under varying:

- Oxygen tensions
- Albumin types (BSA VS lipid-rich BSA)
- Albumin concentrations

26 EV formulations generated using DoE

STEP 2: Multi-parametric EV evaluation


A. Physicochemical characterization

- Size & concentration > Nanoparticle tracking analysis (NTA) > Yield
- Protein quantification > MicroBCA
- Protein per particle (NTA + MicroBCA)


B. Anti-inflammatory assessment

- TNF-α
- IL-6
- IL-1β

Key drivers of liver fibrosis




C. Cellular uptake profiling



- Macrophages (differentiated THP-1)
- Hepatocytes (HEPG2)
- Liver stellate cells (LX-2)


STEP 3: Multi-objective optimization and candidate selection



STEP 4: Modular therapeutic siRNA corona loading

A. siRNA loading

- Thiol-maleimide chemistry
- Albumin-conjugated siRNA




B. Validation




RESULTS

2) Functional evaluation

A. Cellular uptake profile




B. Inflammatory responses mediated by EVs in activated macrophage



Key 2: EV formulations exhibited distinct uptake behaviors and inflammatory responses, supporting the need for integrated multicriteria selection.

3) Integrated candidate selection


Key 3: Integrated multicriteria analysis identified BSA6 as the lead formulation balancing EV physicochemical properties and biological functionality.



4) Programmable therapeutic corona functionalization

A. Functional siRNA delivery using lead EV formulation


- 1) Non-treated
- 2) Free-conjugates (BSA-siGFP)
- 3) LNPs encapsulated with conjugates
- 4) BSA6 coated with conjugates
- 5) Non-optimized EVs coated with conjugates



Key 4: Distinct EV corona environment (BSA6) support functional siRNA surface loading and gene silencing.

RESULTS

1) Design space engineering



Key 1: A model-predicted optimum near 10.6% O₂ guided selection of BSA6 (11% O₂) as a practical lead formulation balancing EV productivity and corona enrichment.

CONCLUSION & FUTURE WORK

These findings establish protein corona engineering as a rational strategy for developing tunable EV-based therapeutics for liver fibrosis. Ongoing studies aim to validate the in vivo therapeutic performance and translational potential of optimized and modularly functionalized EV systems.

ACKNOWLEDGEMENT

The work presented in this poster was conducted in full by Dr Revadee Liam-Or, JC STEM Early Career Research Fellows supported by The Hong Kong Jockey Club Charities Trust.

REFERENCE

- (1) Liam-Or, Revadee et al. "Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent." Nature nanotechnology vol. 19,6 (2024): 846-855.

